4DMedical Receives FDA Clearance for Ventilation-Perfusion Product

4DMedical, an Australia-based medical technology company, has received US FDA clearance for its Ventilation-Perfusion product. The product uses the company's patented XV Technology to enable physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity. The technology powers the FDA-cleared XV Lung Ventilation Analysis Software and its Computed Tomography-enabled counterpart, CT LVAS.

Jaeger™ Medical, a global leader in respiratory diagnostics, has announced a strategic partnership with Pulmonx Corporation to integrate advanced data qualification functionality into its SentrySuite™ platform. The collaboration aims to enhance the platform's ability to support consistent and high-quality clinical decision-making, enabling healthcare providers to identify patients with secondary findings such as severe hyperinflation secondary to emphysema, which may qualify them for innovative treatments like the Zephyr Valve [1].

This partnership is a significant step forward in respiratory diagnostics, as it integrates intelligent data validation and qualification logic into SentrySuite™, streamlining how clinicians interpret and act on respiratory data. Chris Tue, Executive Vice President, Marketing and R&D at Jaeger™ Medical, expressed excitement about the collaboration, highlighting the shared commitment to technological innovation and clinical excellence [1].

Meanwhile, 4DMedical, an Australia-based medical technology company, has received US FDA clearance for its Ventilation-Perfusion product. The product utilizes the company's patented XV Technology, enabling physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity. The technology powers the FDA-cleared XV Lung Ventilation Analysis Software and its Computed Tomography-enabled counterpart, CT LVAS [2].

These advancements in respiratory diagnostics underscore the growing importance of technological innovation in healthcare. The strategic partnership between Jaeger™ Medical and Pulmonx Corporation, as well as the FDA clearance for 4DMedical's product, demonstrate a commitment to improving clinical outcomes through cutting-edge technology.

References:
[1] https://finance.yahoo.com/news/jaeger-pulmonx-announce-strategic-partnership-130000807.html
[2] https://www.4dmedical.com/news/